Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Diabetes Metab J. 2023 May;47(3):325-332. doi: 10.4093/dmj.2022.0349. Epub 2023 Jan 12.
Globally, the number of people with diabetes mellitus has quadrupled in the past three decades, and approximately one in 11 adults worldwide have diabetes mellitus. Since both microvascular and macrovascular diseases in patients with diabetes predispose them to a lower quality of life as well as higher rates of mortality, managing blood glucose levels is of clinical relevance in diabetes care. Many classes of antihyperglycemic drugs are currently approved to treat hyperglycemia in patients with type 2 diabetes mellitus, with several new drugs having been developed during the last decade. Diabetes-related complications have been reduced substantially worldwide. Prioritization of therapeutic agents varies according to national guidelines. However, since the characteristics of participants in clinical trials differ from patients in actual clinical practice, it is difficult to apply the results of such trials to clinical practice. Machine learning approaches became highly topical issues in medicine along with rapid technological innovations in the fields of information and communication in the 1990s. However, adopting these technologies to support decision-making regarding drug treatment strategies for diabetes care has been slow. This review summarizes data from recent studies on the choice of drugs for type 2 diabetes mellitus focusing on machine learning approaches.
在过去的三十年中,全球范围内的糖尿病患者人数增加了四倍,全世界大约每 11 个成年人中就有 1 人患有糖尿病。由于糖尿病患者的微血管和大血管疾病使他们的生活质量降低,死亡率更高,因此控制血糖水平在糖尿病治疗中具有临床意义。目前有许多类别的抗高血糖药物被批准用于治疗 2 型糖尿病患者的高血糖,在过去十年中已经开发出了几种新药物。全球范围内与糖尿病相关的并发症已大大减少。治疗药物的优先级根据国家指南而有所不同。然而,由于临床试验参与者的特征与实际临床实践中的患者不同,因此很难将这些试验的结果应用于临床实践。20 世纪 90 年代,随着信息和通信领域的快速技术创新,机器学习方法成为医学领域的热门话题。然而,采用这些技术来支持针对糖尿病治疗药物治疗策略的决策一直进展缓慢。本综述总结了最近关于 2 型糖尿病药物选择的研究数据,重点介绍了机器学习方法。